News & Events

The TransferAllianz proposes 5 measures to leverage the innovation potential of academic research and drive sustainable economic recovery following the corona crisis.

BERLIN, 28 August 2020 – Aignostics, a spin-off from Charité - Universitätsmedizin Berlin and the Berlin Institute of Health (BIH) pioneering...

T-knife’s proprietary humanized mouse platform (HuTCR) T-cell Receptors expected to provide superior affinity/specificity properties
Series A round led by Versant Ventures and RA Capital Management, with strong participation from seed investors Andera Partners and BIVF

HepaRegeniX has demonstrated proof-of-efficacy in acute liver disease in preclinical studies performed in collaboration with the University Hospital of Tübingen (Germany) and the Mayo Clinic (Rochester, MN, USA).

Ascenion welcomes a new colleague to the Munich office: Cristina Romano joined the company as Legal Counsel in July 2020, bringing over 15 years’ professional experience to the team.

Join us on 24 June and on 1 July 2020 for our webinars, presenting the top licensable projects in the field of gene and cell therapy from Ascenion’s and Oxford University Innovation’s (OUI) portfolios.

Dr Julia Niemann joined Ascenion’s team in Hannover in April 2020 as Technology Scout. Her main focus will be on projects at the Hannover Medical...

Newly founded dentalXrai provides a unique, AI-based platform to improve and speed up the analysis of dental X-ray images. Ascenion, technology transfer partner of the Charité – Universitätsmedizin Berlin, holds equity in the start-up.

Diffratec, a spin-off from the Medical University of Innsbruck (MUI), commercializes breakthrough diffractive elements. These elements, in particular Moiré lenses, are extremely compact and tunable with high speed and precision.

Formula Pharmaceuticals, a partner of the Max Delbrück Center for Molecular Medicine (MDC) has merged with cell therapy specialist CoImmune, with CoImmune as the surviving company. The new entity will continue its strategic partnership with the MDC.

Ascenion and Innovationsstarter Fonds Hamburg acquire equity in Hamburg start-up – innovative therapeutic approach enters clinical testing

Dear clients, partners and technology transfer colleagues,

In these unprecedented and worrying times dominated by the coronavirus pandemic, we remain...

Cardior Pharmaceuticals GmbH has published results of preclinical in vivo studies in Nature Communications showing that its lead compound, CDR132L, can significantly improve the functioning of pathologically altered hearts.

How to increase the social benefit of European research funding? Members of the ASTP’s National Associations’ Advisory Committee (NAAC) recently met representatives of the European Commission (EC) in Brussels to discuss this question.